The new strategic drug development organization was designated to help biopharma companies design and implement drug development strategies.
The strategies take into account the Asia product commercialization opportunity and regulatory hurdles in advance of the standardized development process, the company said.
Consulting services will help customers navigate the new health by linking business strategy, industry expertise and data-driven insights within six practice areas to deliver transformational change.
Quintiles Consulting head and vice president Christian Gabel said that drug development and commercialization in Asia will benefit from their new, strategic approaches.